These presentation papers are provided on the TGA's website solely for the purpose of indicating or suggesting what TGA representatives spoke about to the various conferences and seminars to which it relates. The papers are not legislative in nature and should not be taken to be statements of any law or policy in any way.
The Australian Government Department of Health (of which the TGA is a part) advises that (a) the presentation papers should not be relied upon in any way as representing a comprehensive description of regulatory requirements, and (b) cannot guarantee, and assumes no legal liability or responsibility for, the accuracy, currency or completeness of the information contained in the presentation paper.
Presented by: Jennifer Burnett, Assistant Secretary, Manufacturing Quality Branch, TGA and Paul Crossley, Assistant Director, Manufacturing Quality Branch, TGA
Presented at: Online
Presentation date: Wednesday 6 April 2022
Presentation summary: To provide information on the transition periods and how importers and sponsors can comply with the new requirements, due to reforms having been made to the manufacturing, labelling and packaging requirements for Medicinal Cannabis Products manufactured or supplied in Australia.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.